Tate & Lyle (OTCMKTS: TATYY) and Yield10 Bioscience (NASDAQ:YTEN) are both consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.
Earnings & Valuation
This table compares Tate & Lyle and Yield10 Bioscience’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tate & Lyle||$3.73 billion||1.00||$334.66 million||$2.55||12.62|
|Yield10 Bioscience||$940,000.00||18.14||-$9.39 million||($3.29)||-0.52|
Tate & Lyle has higher revenue and earnings than Yield10 Bioscience. Yield10 Bioscience is trading at a lower price-to-earnings ratio than Tate & Lyle, indicating that it is currently the more affordable of the two stocks.
This table compares Tate & Lyle and Yield10 Bioscience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tate & Lyle||N/A||N/A||N/A|
Risk and Volatility
Tate & Lyle has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, Yield10 Bioscience has a beta of 3.19, meaning that its share price is 219% more volatile than the S&P 500.
Tate & Lyle pays an annual dividend of $1.41 per share and has a dividend yield of 4.4%. Yield10 Bioscience does not pay a dividend. Tate & Lyle pays out 55.3% of its earnings in the form of a dividend.
This is a breakdown of recent ratings and target prices for Tate & Lyle and Yield10 Bioscience, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tate & Lyle||0||2||3||0||2.60|
Institutional & Insider Ownership
0.3% of Tate & Lyle shares are held by institutional investors. Comparatively, 9.3% of Yield10 Bioscience shares are held by institutional investors. 11.2% of Yield10 Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Tate & Lyle beats Yield10 Bioscience on 9 of the 14 factors compared between the two stocks.
About Tate & Lyle
Tate & Lyle PLC, together with its subsidiaries, provides ingredients and solutions to the food, beverage, and other industries in the United States, the United Kingdom, other European countries, and internationally. It operates through two segments, Speciality Food Ingredients and Bulk Ingredients. The company offers texturants, including corn-based starches, clean-label starches, and stabilizer systems; sweeteners, such as high intensity sweeteners and specialty sweeteners; and health and wellness ingredients comprising dietary fibers and oat proteins. In addition, the company is involved in blending, in-house treasury, pension, and reinsurance businesses; citric acid and sucralose production; and research and development and in-house financing businesses, as well as the provision of acidulants and grains. Tate & Lyle PLC was incorporated in 1903 and is headquartered in London, the United Kingdom.
About Yield10 Bioscience
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.
Receive News & Ratings for Tate & Lyle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tate & Lyle and related companies with MarketBeat.com's FREE daily email newsletter.